Bedside Snapshot
- Normal (Adult)
- Desirable <200 mg/dL (<5.2 mmol/L); borderline 200–239; high ≥240 mg/dL (≥6.2 mmol/L). Risk decides treatment: check LDL-C and non-HDL-C against the goal
- Critical Values
- No universal critical value: interpret by trend and clinical context. ≥300 mg/dL (≥7.8 mmol/L): makes FH more likely; measure LDL-C
- High Suggests
- Familial hypercholesterolemia (very high LDL-C)
- Hypothyroidism, nephrotic syndrome, cholestasis
- Corticosteroids, cyclosporine, protease inhibitors
- Saturated or trans fat intake; obesity or diabetes
- Low Suggests
- Rarely meaningful on its own: acute illness or sepsis, malnutrition, severe liver disease, hyperthyroidism, or lipid-lowering therapy
- Act Now If
- No total cholesterol value needs emergency treatment. Triglycerides ≥1,000 mg/dL: pancreatitis risk; check lipase with abdominal pain. Acute coronary syndrome: treat per protocol; do not wait for lipids
- Watch Out For
- Fasting is not required, but a value drawn during acute illness reads falsely low. Repeat after recovery before judging long-term risk
Reference & Critical Ranges
Lab-specific ranges: Every lab sets its own intervals, based on its analyzer and the population it serves. Read the range printed on your report. The values below are typical.
Reference ranges
| Population | Conventional | SI | Notes |
|---|---|---|---|
| Adult | Desirable <200 mg/dL; borderline 200–239; high ≥240 | <5.2; 5.2–6.2; ≥6.2 mmol/L | Same for men and women. Fasting not required. Treatment decisions use risk-based LDL-C and non-HDL-C goals, not this table. Universal lipid screening from age 19, repeated about every 5 years (2026 ACC/AHA) |
| Pregnancy | No pregnancy-specific range | — | Total cholesterol rises in pregnancy and falls back after delivery; do not use pregnancy values for long-term risk |
| Older adult | Same as adult | — | No separate range. Age is part of the PREVENT risk estimate used for treatment |
| Children and adolescents (2–19 years) | Acceptable <170; borderline 170–199; high ≥200 mg/dL | <4.4; 4.4–5.1; ≥5.2 mmol/L | National Heart, Lung, and Blood Institute (NHLBI) pediatric cut points |
Severity & critical values
| Level | Conventional | SI | What it means |
|---|---|---|---|
| Desirable | <200 mg/dL | <5.2 mmol/L | Lowest total-cholesterol category; still check LDL-C and HDL-C, because total cholesterol alone does not define risk |
| Borderline high | 200–239 mg/dL | 5.2–6.2 mmol/L | Calculate non-HDL-C and check LDL-C; decide on risk-based treatment |
| High | ≥240 mg/dL | ≥6.2 mmol/L | Look for a secondary cause and measure LDL-C directly before treatment decisions |
| Very high | ≥300 mg/dL | ≥7.8 mmol/L | A very high value makes familial hypercholesterolemia (FH) more likely, but FH can also occur at lower totals. Heterozygous FH is about 1 in 200 to 250 in the population (ESC/EAS 2019); measure LDL-C and take a family history |
Critical values: Total cholesterol has no universal critical value. Read it by trend and clinical context. A value of 300 mg/dL or more makes FH more likely. That is a reason to measure LDL-C and consider FH evaluation. It is not an emergency.
Conversion: mg/dL × 0.0259 = mmol/L
Estimated total cholesterol (check, not a substitute for measurement)
Total cholesterol ≈ LDL-C + HDL-C + (triglycerides ÷ 5)
Typical value: the estimate should land within assay error of the measured total cholesterol. The triglycerides ÷ 5 term stands in for VLDL cholesterol (Friedewald). Use it only when triglycerides are below 400 mg/dL.
Causes of Abnormal Results
High (Hypercholesterolemia, total cholesterol ≥240 mg/dL)
| Mechanism | Common causes | Bedside clue |
|---|---|---|
| LDL receptor defect (genetic) | Familial hypercholesterolemia (FH); heterozygous FH is common, homozygous FH is rare | Very high LDL-C, tendon xanthomas, corneal arcus before age 45, premature coronary disease in a relative |
| Polygenic or combined genetic lipid disorder | Polygenic hypercholesterolemia; familial combined hyperlipidemia | Moderate elevation; triglycerides often high too; strong family history |
| Hypothyroidism | Less LDL receptor activity, so less LDL clearance | Fatigue, weight gain, cold intolerance; check TSH |
| Nephrotic syndrome | Liver overproduces lipoproteins as protein is lost in urine | Edema and marked proteinuria; check urine protein |
| Cholestatic liver disease | Reduced biliary cholesterol excretion | Jaundice, pruritus, raised alkaline phosphatase or GGT |
| Diabetes, obesity, metabolic syndrome | Insulin resistance; more VLDL and triglycerides, lower HDL-C | Raised triglycerides and glucose; low HDL-C |
| Medications | Corticosteroids, cyclosporine, tacrolimus, protease inhibitors, anabolic steroids; thiazides (modest rise); some progestins (variable) | Review the medication list before labelling primary hypercholesterolemia |
| Diet and pregnancy | Saturated and trans fat intake; pregnancy (hormonal rise) | Diet history; pregnancy status |
Do not label a patient with primary hypercholesterolemia first: Check TSH, urine protein, liver tests and glucose, then review the medications. Hypothyroidism and nephrotic syndrome are common causes, and both can be treated.
Low (Hypocholesterolemia)
A low total cholesterol is rarely the thing to treat. It usually points to acute illness, malnutrition, liver failure or therapy. Find the cause. Don't chase the number.
| Mechanism | Common causes | Bedside clue |
|---|---|---|
| Acute illness | Sepsis, acute infection, acute myocardial infarction, trauma, major surgery (acute-phase fall) | Recent illness; value rises again with recovery |
| Malnutrition or malabsorption | Low intake or poor fat absorption | Weight loss, steatorrhea, low albumin |
| Severe liver disease | Reduced hepatic cholesterol synthesis (cirrhosis, hepatic failure) | Jaundice, ascites, coagulopathy |
| Hyperthyroidism | Faster cholesterol turnover | Tachycardia, tremor, weight loss; check TSH |
| Malignancy | Advanced cancer | Known or suspected cancer with cachexia |
| Lipid-lowering therapy | Statins, ezetimibe, PCSK9 inhibitors (expected effect) | Medication list; compare with prior values |
| Rare genetic disorders | Hypobetalipoproteinemia; abetalipoproteinemia | Fat malabsorption and neurologic signs in abetalipoproteinemia; specialist referral |
Interpretation & Bedside Approach
Step-by-step approach
- Is it real? Confirm the specimen and the patient's recent state. Repeat a value that does not fit the clinical picture before acting on it.
- How sick is the patient? During acute coronary syndrome, sepsis, trauma or major surgery, total cholesterol falls. Treat the acute condition on its own timeline; do not wait for a lipid result.
- Acute or chronic, and what is the trend? Compare with prior values. A single high value needs a repeat before long-term treatment decisions, and averaging improves reliability.
- Calculate the derived values. Non-HDL-C = total cholesterol − HDL-C. Check LDL-C (measured or calculated; see below) and triglycerides.
- Classify by risk, not by total cholesterol alone. The 2026 ACC/AHA multisociety dyslipidemia guideline uses 10-year PREVENT-ASCVD risk groups and LDL-C and non-HDL-C goals.
- Escalate or disposition. Acute chest pain follows the ACS pathway. Triglycerides of 1,000 mg/dL or more are the usual severe threshold for pancreatitis risk; ESC/EAS 2019 places clinically significant risk above 880 mg/dL (10 mmol/L). Very high values prompt FH evaluation and a referral pathway.
Pattern and what it suggests
| Pattern | Suggests |
|---|---|
| High total, high LDL-C, normal triglycerides | Primary hypercholesterolemia (FH or polygenic) or a secondary cause such as hypothyroidism or nephrotic syndrome |
| High total, high triglycerides, low HDL-C | Insulin resistance, obesity, or familial combined hyperlipidemia |
| High total, high HDL-C | A high HDL-C does not offset a high LDL-C. Check LDL-C and non-HDL-C before reassurance |
| Low total, recent sepsis or MI | Acute-phase fall; repeat after recovery |
| Low total with low LDL-C and low triglycerides | Malabsorption, liver failure, hyperthyroidism, or lipid-lowering therapy |
Risk-based goals (2026 ACC/AHA multisociety guideline)
Forget the total as a target. The 2026 guideline brings back absolute LDL-C goals, with non-HDL-C as the second target. The 10-year PREVENT-ASCVD score sorts people into four groups: low (below 3%), borderline (3% to below 5%), intermediate (5% to below 10%), and high (10% or more).
| Risk group | LDL-C goal | Non-HDL-C goal | Action |
|---|---|---|---|
| Low (below 3%) | Not stated on this page | Not stated on this page | Lifestyle first; reassess risk with PREVENT and risk-enhancing factors |
| Borderline (3% to <5%) | <100 mg/dL | <130 mg/dL | LDL-lowering therapy is reasonable |
| Intermediate (5% to <10%) | <100 mg/dL | <130 mg/dL | LDL-lowering therapy is recommended after a clinician-patient discussion |
| High (10% or more) | <70 mg/dL | <100 mg/dL | Lipid-lowering therapy to reach these goals |
| Very high-risk ASCVD (2 or more major ASCVD events, or 1 event plus 2 or more high-risk features) | <55 mg/dL | <85 mg/dL | Intensive therapy to reach these goals |
Non-HDL cholesterol
Non-HDL-C = total cholesterol − HDL-C
Typical value: use the goal in the table above. Non-HDL-C works at any triglyceride level, and no fast is needed.
Other items the 2026 guideline adds
- Lipoprotein(a): measure once in every adult. Lp(a) cholesterol is part of total cholesterol and is not lowered by lifestyle change.
- ApoB: may help assess residual risk after LDL-C and non-HDL-C goals are reached.
- Coronary artery calcium: may help reclassify risk in adults with borderline or intermediate risk, as part of the Calculate, Personalize, Reclassify (CPR) approach.
Acute coronary syndrome and triglycerides
With an ACS, give high-intensity statin therapy whatever the lipid level says, per the 2025 ACC/AHA acute coronary syndrome guideline. The panel never holds up ACS treatment. Triglycerides at 1,000 mg/dL or more on that same panel mark a severe pancreatitis threshold (ESC/EAS 2019 uses 880 mg/dL, 10 mmol/L). If the patient has abdominal pain, check lipase.
Special Populations
| Population | What changes | Clinical implication |
|---|---|---|
| Children and adolescents | NHLBI cut points (Reference & Critical Ranges) | NHLBI 2011 recommends one screen at ages 9–11 and one at ages 17–21; screen earlier if there is a family history of premature coronary disease or familial hyperlipidemia |
| Pregnancy | Total cholesterol rises with hormonal changes | Do not diagnose or treat hyperlipidemia from pregnancy values. Statin labelling changed in 2021 (see Clinical Pearls) |
| Older adults | No separate range | Treatment depends on the PREVENT risk estimate (valid for ages 30–79) and LDL-C and non-HDL-C goals, not on total cholesterol |
| CKD and dialysis | Nephrotic-range proteinuria raises cholesterol | CKD is a risk-enhancing condition. KDIGO 2013 recommends statin therapy for adults aged 50 or older with CKD, and suggests it for adults aged 18–49 with CKD plus a coronary, diabetes, prior ischemic stroke or 10% or higher 10-year risk indication. For dialysis-dependent patients, KDIGO 2013 suggests not starting a statin; a statin already in use at dialysis start is continued |
| Liver disease | Cholestasis raises it; cirrhosis and hepatic failure lower it | Interpret a low value as a marker of liver failure, not a treatment target |
Pediatric note: On this page, only the NHLBI cut points set pediatric total cholesterol thresholds. Any child with a high value, or with FH, needs specialist lipid care.
Interfering Factors & Pitfalls
Collection and handling
| Factor | Effect | Why | Avoid or fix |
|---|---|---|---|
| Standing before the draw | ↑ (higher value) | Hemoconcentration as fluid shifts into the vessels | Draw with the patient seated or lying if possible; record posture |
| Prolonged tourniquet | ↑ (higher value) | Local hemoconcentration | Limit tourniquet time; release it before the draw is complete |
| Fasting status | Little effect on total cholesterol | Total cholesterol changes little after a meal; triglycerides change much more | Non-fasting total cholesterol is acceptable for screening |
Medications and supplements
| Factor | Effect | Why | Avoid or fix |
|---|---|---|---|
| Corticosteroids, cyclosporine, tacrolimus | ↑ | Raise LDL-C and total cholesterol | Note the drug and dose when interpreting a high value |
| Protease inhibitors, anabolic steroids | ↑ (LDL-C); anabolic steroids lower HDL-C | Drug-induced dyslipidemia | Review the medication list |
| Statins, ezetimibe, PCSK9 inhibitors, fibrates, niacin, bile acid sequestrants | ↓ | Expected therapeutic effect | Compare with the pre-treatment value; judge against the goal, not a fixed number |
Physiologic and biologic factors
| Factor | Effect | Why | Avoid or fix |
|---|---|---|---|
| Acute illness, sepsis, MI, trauma, surgery | ↓ (false low for baseline) | Acute-phase fall in lipoproteins | Repeat after recovery before long-term decisions |
| Pregnancy | ↑ | Hormonal rise | Do not use for long-term risk or treatment decisions |
| Hypothyroidism / nephrotic syndrome | ↑ | Reduced LDL clearance; hepatic overproduction | Check TSH and urine protein |
Assay and reporting
- Method: total cholesterol is measured directly by enzymatic assay, so no calculation is needed. LDL-C may be calculated. The Friedewald equation is invalid at triglycerides of 400 mg/dL or higher.
- Reporting: ask which LDL-C method the lab used before you compare values across labs or over time.
Common misinterpretations
- A normal total cholesterol does not mean low risk. LDL-C, non-HDL-C and risk factors drive the treatment decision.
- Don't let a high HDL-C talk you out of a high LDL-C.
- A low total during illness is not a baseline. It is no sign of good health.
- You don't need to fast for a total cholesterol or a screening lipid panel.
Physiology & Test Basics
What it measures
Total cholesterol adds up all the cholesterol the lipoproteins carry in the blood, and reports it as one number. Think of it as a screen. Treatment decisions rest on LDL-C, HDL-C, non-HDL-C and triglycerides, and each has its own page.
Physiology & regulation
- Cell membranes: cholesterol gives structure to every cell membrane.
- Steroid hormones: it is the precursor for cortisol, aldosterone, testosterone, estradiol and progesterone.
- Bile acids: the liver turns cholesterol into bile acids, which digest fat.
- Vitamin D: sunlight turns skin cholesterol into vitamin D3.
- Lipoproteins: LDL-C delivers cholesterol to the tissues. HDL-C carries it back toward the liver. VLDL and IDL carry triglycerides and cholesterol. Lp(a) carries cholesterol plus an apolipoprotein(a) component.
- Sources: the liver and other cells make most of the body's cholesterol. Diet contributes less.
How it is measured
Total cholesterol is measured on serum or plasma. Draw it in the tube the lab requires. You will usually see it reported on a lipid panel. Fasting is not required, and a non-fasting sample is acceptable for screening. The lab reports LDL-C either measured directly or calculated.
Why it matters
Total cholesterol is the first screen for hyperlipidemia. It cannot tell atherogenic lipoproteins from protective ones. In emergency and critical care it matters for two reasons. Acute illness pulls it down. And a very high value can signal FH in a patient who presents with early coronary disease.
Clinical Pearls
"Total cholesterol tells the total story, not the whole story": Low HDL-C on a borderline total can carry more risk than a high total with high HDL-C. Always read the whole panel, then check the risk-based goal.
Fasting is not required: You don't need to fast for this one. Total cholesterol hardly shifts after a meal, so a non-fasting panel does the screening job. Triglycerides are where food shows up.
Check thyroid function and urine protein: hypothyroidism and nephrotic syndrome are common, and both can be corrected. Both also push total cholesterol up. In new hyperlipidemia, check TSH and urine protein, especially with fatigue, weight gain or edema.
Transport and ACS: lipid results leave your field and transport care exactly where it was. Treat ACS per protocol, and never let a lipid panel slow it down.
Nursing: repeat after recovery: a draw taken during sepsis, MI, trauma or surgery reads falsely low. Write the context on the order. Repeat the panel after recovery, before you decide on long-term therapy.
Lp(a) once in every adult: lipoprotein(a) cholesterol rides inside the LDL-C number. When Lp(a) runs high, LDL-C can overstate the LDL-particle component. Neither statins nor lifestyle change lower it meaningfully. The 2026 guideline says one measurement for every adult.
Pregnancy and statins: Pregnancy pushes total cholesterol up, and that rise is no reason to treat. FDA asked manufacturers in 2021 to drop the blanket statin contraindication, yet it still advises most pregnant patients to stop. For very-high-risk patients, such as those with homozygous FH or a prior heart attack or stroke, the call is individual. Statins are safe for patients who are not pregnant but may become pregnant. On breastfeeding, FDA advises against it while on a statin. Patients who need ongoing statin therapy should use formula or other alternatives.
Think FH with a high LDL-C and clues: Tendon xanthomas, corneal arcus before age 45, or premature coronary disease in a first-degree relative should make you consider FH. Those patients need intensive treatment, and their family gets cascade screening.
References
- Writing Committee Members; Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., et al. (2026). 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of dyslipidemia: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 153(17), e1154–e1276. https://doi.org/10.1161/CIR.0000000000001423
- Rao, S. V., O'Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., et al. (2025). 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 151(13), e771–e862. https://doi.org/10.1161/CIR.0000000000001309
- Nordestgaard, B. G., Langsted, A., Mora, S., Kolovou, G., Baum, H., Bruckert, E., et al. (2016). Fasting is not routinely required for determination of a lipid profile: Clinical and laboratory implications including flagging at desirable concentration cut-points. A joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. European Heart Journal, 37(25), 1944–1958. https://doi.org/10.1093/eurheartj/ehw152
- Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. (2011). Integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Full report (landmark guideline). National Institutes of Health. https://www.nhlbi.nih.gov/health-topics/integrated-guidelines-for-cardiovascular-health-and-risk-reduction-in-children-and-adolescents/integrated-guidelines-for-cardiovascular-health-and-risk-reduction-in-children-and-adolescents-full-report
- Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). (2020). 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal, 41(1), 111–188. https://doi.org/10.1093/eurheartj/ehz455
- U.S. Food and Drug Administration. (2021). Drug Safety Communication: FDA requests removal of the pregnancy contraindication for statins (July 2021). https://www.fda.gov/media/150774/download
- Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972). Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge (landmark formula). Clinical Chemistry, 18(6), 499–502. https://doi.org/10.1093/clinchem/18.6.499
- Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. (2013). KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney International Supplements, 3(3), 259. https://doi.org/10.1038/kisup.2013.27
Medical Disclaimer
- For Educational Purposes Only: This content is intended for educational reference and should not be used for clinical decision-making.
- Not a Substitute for Professional Judgment: Always consult your local protocols, institutional guidelines, and supervising physicians.
- Verify Before Acting: Users are responsible for verifying information through authoritative sources before any clinical application.
AI Assistance Notice
AI was used to assist in organizing, paraphrasing, and formatting this information.